Parallel group comparison, single dose level of 5 forms of the investigational study drug.

Parallel group comparison, single p.o. dose escalation (3 dose levels) of 4 forms investigational study drug and placebo administered to two sequential cohorts. Dose Level 1 will be administered to the first cohort. Dose Levels 2 and 3 will be administered to a subsequent cohort. Dose levels in this cohort are separated by a 7-day washout period. Doses to be determined by review of data from Part 1.

Parallel group comparison of 4 active treatments dosed p.o. x 4 days. Each active is dosed in a 2-period placebo-controlled crossover separated by a 5-day washout. Doses to be determined by review of data from Part 2.

Two-period single p.o. dose fasted/fed crossover separated by 5-day washout period. Dose to be determined by review of data from Part 2.

Extended-release form

Clinically observed adverse events include findings from physical examination, vital sign, ECG and laboratory assessments (hematological and clinical chemistry laboratory panels). Participant report includes any side effect reported by a participant during the study.

To evaluate drug exposure over specified measurement time frame

To evaluate peak drug concentration achieved during specified measurement time frame

To evaluate time to achieve peak concentration during specified measurement time frame

To evaluate rate of drug elimination

To evaluate time over which drug concentration is decreased by half

To evaluate rate of drug clearance

To compare single dose oral bioavailability in fed and fasted states